Proventil HFA and ventolin have similar safety profiles during regular use

Chest

Volumn 113, Issue 2, 1998, Pages 290-296

  Tinkelman, David G ^b   Bleecker, Eugene R ^a   Ramsdell, Joe ^c   Eekholm, Bruce P ^d   Klinger, Nancy M ^d   Colice, Gene L ^d   Slade, Herbert B ^d  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^c UCSD MEDICAL CENTER   (United States)

^d 3M COMPANY   (United States)

Author keywords

Albuterol; Asthma; HFA 134a propellant

Indexed keywords

NORFLURANE; PROVENTIL HFA; SALBUTAMOL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ASTHMA; BRONCHODILATATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SCORING SYSTEM; SLEEP DISORDER; SPIROMETRY; UPPER RESPIRATORY TRACT INFECTION;

EID: 0031932307     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.113.2.290     Document Type: Article

References (30)

1. D'Souza S. The Montreal Protocol and essential use exemptions. J Aerosol Med 1995; 8(suppl 1):13-17
2. Molina MJ, Rowland FS. Stratospheric sink for chlorofluoromethanes: chlorine atom catalysed destruction of ozone. Nature 1974; 249:810-12
3. Manzer LE. The CFC-ozone issue: progress on the development of alternatives to CFCs. Science 1990; 249:31-35
4. Physicians desk reference. Montvale, NJ: Medical Economics, 1996
5. Bhagat R, Swystun VA, Cockeroft DW. Salbutamol-induced increased airway responsiveness to allergen and reduced protection versus methacholine: dose response. J Allergy Clin Immunol 1996; 97:47-52
6. Inman MD, O'Byrne PM. The effect of regular inhaled albuterol on exercise-induced bronchoconstriction. Am J Respir Crit Care Med 1996; 153:65-69
7. Spitzer WO, Suissa S, Ernst P, et al. The use of β-agonists and the risk of death and near death from asthma. N Engl J Med 1992; 326:501-06
8. Ernst P, Habbick B, Suissa S, et al. Is the association between inhaled beta-agonist use and life-threatening asthma because of confounding by severity? Am Rev Respir Med 1993; 148:75-79
9. Mullen M, Mullen B, Carey M. The association between β-agonist use and death from asthma. JAMA 1993; 270: 1842-45
10. Van Schayck CP, Graafsma SJ, Visch MB, et al. Increased bronchial hyperresponsiveness after inhaling salbutamol during 1 year is not caused by subsensitization to salbutamol. J Allergy Clin Immunol 1990; 86:793-800
11. Van Schayck CP, Cloosterman SGM, Hofland ID, et al. How detrimental is chronic use of bronchodilators in asthma and chronic obstructive pulmonary diseased? Am J Respir Crit Care Med 1995; 151:1317-19
12. Bleecker ER, Tinkleman DG, Ramsdell J. et al. Proventil HFA provides bronchodilation comparable to Ventolin over 12 weeks of regular use in asthmatics. Chest 1998; 113:283-89
13. Crapo RO, Morris AH, Gardner RM. Reference spirometric values using techniques and equipment that meet ATS recommendations. Am Rev Respir Dis 1981; 123:659-64
14. Drazen JM, Israel E, Boushey HA, et al. Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. N Engl J Med 1996; 335:841-47
15. Donnell D, Harrison LI, Simmons J, et al. 28-day safety study of the HFA-134a 3M CFC-free system in healthy volunteers [abstract]. Am J Respir Crit Care Med 1995; 151(suppl):A57
16. Chapman KR, Kesten S, Szalai JP. Regular vs as-needed inhaled salbutamol in asthma control. Lancet 1994; 343: 1379-82
17. Van Schayck CP, Dompeling E, van Herwaarden CLA, et al. Bronchodilator treatment in moderate asthma or chronic bronchitis: continuous or on demand? A randomised controlled study. BMJ 1991; 303:1426-31
18. Van Schayck CP, Rutten-von Molken MP, van Doorslaer EK. et al. Two-year bronchodilator treatment in patients with mild airflow obstruction: contradictory effects on lungs function and quality of life. Chest 1992; 102:1384-91
19. Wahedna I, Wong CS, Wisniewski AFZ, et al. Asthma control during and after cessation of regular beta-agonist treatment. Am J Respir Crit Care Med 1993; 148:707-12
20. Reddel HK, Salome CM, Peat JK, et al. Which index of peak expiratory flow is most useful in the management of stable asthma? Am J Respir Crit Care Med 1996; 151:1320-25
21. Wang Z, Walker BAM, Weir TD, et al. Effect of chronic antigen and β-agonist exposure on airway remodeling in guinea pigs. Am J Respir Crit Care Med 1995; 152:2097-2104
22. Cockcroft DW, Swystun VA, Bhagat R. Interaction of inhaled β-agonist and inhaled corticosteroid on airway responsiveness to allergen and methacholine. Am J Respir Crit Care Med 1995; 152:1483-89
23. Sears MR, Taylor DR, Print CG, et al. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet 1990; 336:1391-96
24. Taylor DR, Sears MR, Herbison EM, et al. Regular inhaled β-agonist in asthma: effects on exacerbations and lung function. Thorax 1993; 48:134-38
25. Van Ganse E, van der Linden PD, Leufkens HGM, et al. Asthma medications and disease exacerbations: an epidemiological study as a method for asthma surveillance. Eur Respir J 1995; 8:1856-60
26. Bremner P, Siebers R, Crane J, et al. Partial vs full β-receptor agonism: a clinical study of inhaled albuterol and fenoterol. Chest 1996; 109:957-62
27. Laitinen LA, Laitinen A, Haahtela T. Airway mucosal inflammation even in patients with newly diagnosed asthma. Am Rev Respir Dis 1993; 147:697-704
28. Haahtela T, Jarvinen M, Kava T, et al. Comparison of a β-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med 1991; 325:388-92
29. Overbeek SE, Kerstjens HA, Bogaard JM, et al. Is delayed introduction of inhaled corticosteroids harmful in patients will obstructive airways disease (asthma and COPD)? Chest 1996; 110:35-41
30. Trigg CJ, Manolitsas ND, Wang J, et al. Placebo-controlled immunopathologic study of 4 months of inhaled corticosteroids in asthma. Am J Respir Crit Care Med 1994; 150:17-22